Clinical Trial: NCT06483282
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | Jin Ying |
| Information Provided By: | Zhejiang Cancer Hospital |
| Last Update Posted: | 2026-09-11 |
Study Overview
Brief Summary
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was performed within 4-8 weeks after the above treatment (the operation was performed 4 weeks after apatinib was discontinued). According to the results of MDT discussion, adebrelimab combined with apatinib mesylate combined with or without radiotherapy was started 4 weeks after surgery. Preoperative prophylactic radiotherapy (PCI) is recommended for patients with preoperative stage N1. Patients with postoperative stage N1 received postoperative thoracic radiotherapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Adebrelimab
- Drug: Apatinib Mesylate
- Drug: Etoposide
- Drug: Carboplatin
Other Study ID Numbers
- IRB-2024-420
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Jin Ying |
| Information Provided By: | Zhejiang Cancer Hospital |
| Last Update Posted: | 2026-09-11 |
Study Overview
Brief Summary
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was performed within 4-8 weeks after the above treatment (the operation was performed 4 weeks after apatinib was discontinued). According to the results of MDT discussion, adebrelimab combined with apatinib mesylate combined with or without radiotherapy was started 4 weeks after surgery. Preoperative prophylactic radiotherapy (PCI) is recommended for patients with preoperative stage N1. Patients with postoperative stage N1 received postoperative thoracic radiotherapy.
Official Title
Conditions
Intervention / Treatment
- Drug: Adebrelimab
- Drug: Apatinib Mesylate
- Drug: Etoposide
- Drug: Carboplatin
Other Study ID Numbers
- IRB-2024-420